Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check company focused on the domestic pharmaceutical manufacturing and life sciences sector. The SPAC filed its annual report on Form 10-K with the SEC on April 15, 2026, reflecting its continued search for an acquisition target within the U.S. drug production and healthcare supply-chain space. DMAA positions itself around the ongoing policy and industry push to reshore pharmaceutical manufacturing away from foreign suppliers. The company operates within the healthcare and biotechnology SPAC category, a segment that has drawn sustained institutional attention in recent years. Visit SpacDesk and sign up for full data, filings, and analytics on DMAA and hundreds of other active SPACs.